Solid Biosciences (SLDB) Debt to Equity (2024 - 2026)
Quarterly results put Debt to Equity at $0.01 for Q1 2026, down 45.07% from a year ago — trailing twelve months through Mar 2026 was $0.01 (down 45.07% YoY), and the annual figure for FY2025 was $0.05, up 122.68%.
Solid Biosciences has reported Debt to Equity over the past 3 years, most recently at $0.01 for Q1 2026.
- Debt to Equity reached $0.01 in Q1 2026 per SLDB's latest filing, down from $0.05 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.05 in Q4 2025 and bottomed at $0.01 in Q1 2026.
- Median Debt to Equity over the past 3 years was $0.02 (2025), compared with a mean of $0.02.
- The largest annual shift saw Debt to Equity skyrocketed 122.68% in 2025 before it crashed 45.07% in 2026.
- Over 3 years, Debt to Equity stood at $0.02 in 2024, then surged by 122.68% to $0.05 in 2025, then tumbled by 82.48% to $0.01 in 2026.
- Business Quant data shows Debt to Equity for SLDB at $0.01 in Q1 2026, $0.05 in Q4 2025, and $0.03 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.06 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.01 |
| Dec 31, 2025 | 0.05 |
| Sep 30, 2025 | 0.03 |
| Jun 30, 2025 | 0.02 |
| Mar 31, 2025 | 0.02 |
| Dec 31, 2024 | 0.02 |
| Sep 30, 2024 | 0.02 |